(MYCO) – Globe Newswire
-
Mydecine Innovations Group Receives Two Notice of Allowances from USPTO for its MYCO-005 and MYCO-006 Family of Compounds
-
Mydecine Innovations Group Announces Director Resignation
-
Mydecine Announces Update Regarding the Special Access Program
-
Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreements
-
Mydecine Innovations Group Announces Listing on the Canadian Securities Exchange and Delisting from the NEO
-
Mydecine Innovations Group Announces Expected U.K. Dual Listing Admission Date
-
Mydecine Innovations Announces Amended Press Release Relating to the Closing of Prospectus Supplement Financing
-
Mydecine Innovations Announces Closing of Prospectus Supplement Financing
-
Mydecine Innovations Group Files Prospectus Supplement
-
Mydecine Reports Financial Results for the Second Quarter of Fiscal Year 2023
-
Mydecine Innovations Group Provides Corporate Update
-
Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreement and Provides Update on Its Board of Directors
-
Mydecine Reports Financial Results for the First Quarter of Fiscal Year 2023
-
Mydecine Reports its 2023 Annual General Shareholders' Meeting Results
-
Mydecine Reports Positive Preclinical Results on the MYCO-006 Series of its Short-Acting MDMA Analogues
-
Mydecine Innovations Group Provides Corporate Update
-
Mydecine Reports Financial Results for the Year Ended December 2022
-
Mydecine Announces Debt Settlements
-
Mydecine Innovations Group Closes Sale of Its Wholly-Owned Subsidiary, Mindleap Health Inc.
-
Mydecine Innovations Group Files Prospectus Supplement and Announces Closing Under Share Subscription Agreement
-
Mydecine Reports Financial Results for the Third Quarter of Fiscal Year 2022
-
Mydecine Innovations Group Signs a Letter of Intent to Sell its Wholly-Owned Subsidiary, Mindleap Health Inc.
-
Mydecine Innovations Group Announces Common Share Subscription Agreement
-
Mydecine Innovations Group Announces Private Placement; Interim Changes to Management and Board of Directors
-
Mydecine Reports Financial Results for the Second Quarter of Fiscal Year 2022
-
Mydecine Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting MDMA Analogs
-
U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation
-
Mydecine Provides Company Update; Welcomes New Board Member
-
Mydecine Announces First Quarter 2022 Financial Results and Highlights
-
Mydecine Reports Financial Results for the Fiscal Year 2021 and Provides a Business Update
-
Mydecine Receives Conditional IRB Approval for Phase 2b Smoking Cessation Study
-
Mydecine To Attend March Investor Conferences
-
Mydecine Reports Positive Pre-IND Meeting With FDA For MYCO-001 Smoking Cessation Study
-
Mydecine Announces MYCO-005 Family of Improved Safety Microdose Novel Molecules
-
Mydecine’s Exclusive Dealer Identified as Licensed Psilocybin and MDMA Supplier in Canada
-
Mydecine Welcomes Dr. Victoria Hale as Newest Independent Board Member
-
Mydecine Submits Pre-Investigational New Drug Briefing Package to the FDA for MYCO-001 Seamless Phase 2/3 Smoking Cessation Clinical Trial
-
Mydecine Partners with Combat Stress to Treat Post-Traumatic Stress Disorder in Veterans
-
Mydecine Signs LOI with The Newly Institute to Provide Psychedelic-Assisted Psychotherapy to Patients under Health Canada’s Special Access Program
-
Mydecine to Launch Special Access Support and Supply Program in Canada Expanding Access to Psychedelic-Assisted Psychotherapy For Patients
-
IBN (InvestorBrandNetwork) Announces Latest Episode of The Bell2Bell Podcast featuring Josh Bartch, CEO of Mydecine Innovations Group Inc.
-
Mydecine Achieves Innovative Supercomputing Artificial Intelligence Modeling in Psychedelic Drug Development Enabling Quick Screening of Billions of Compounds
-
Mydecine Innovations Group Engages JBN Partners, LLC for Marketing Services
-
IBN (InvestorBrandNetwork) Announces Gamechangers LIVE Interview with Mydecine Innovations Group Inc. CEO Joshua Bartch
-
Mydecine Signs LOI with Maya to Co-Develop a Novel Prescription Digital Therapeutic Platform Aiming to Further Increase Safety, Efficacy, and Accessibility of Psychedelic-Assisted Treatments
-
Mydecine Secures Financing and Provides Company Update on Clinical Trials, Drug Development and Technology Initiatives
-
Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs
-
Mydecine Reports Third Quarter 2021 Financial Results and Provides Business Update
-
Mydecine’s Chief Medical Officer, Dr. Rakesh Jetly, to Participate at Horizons’ Veterans & Families Forum on November 10, 2021
-
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Leader in Emerging Psychedelic-Assisted Psychotherapy Industry
Back to MYCO Stock Lookup
